{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:16:39Z","timestamp":1790712999775,"version":"4.1.0"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T00:00:00Z","timestamp":1765152000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"\n Background<\/jats:title>\n Modakafusp alfa is a novel immunocytokine comprising two attenuated interferon-\u03b12b molecules fused to an anti-CD38 IgG4 monoclonal antibody. Modakafusp alfa has shown immune cell activation and antitumor activity in preclinical mouse models, including in combination with an anti-programmed cell death (PD-1) receptor in tumors that do not express CD38, and demonstrated clinical responses and immune activation in patients with relapsed\/refractory multiple myeloma.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n In phase Ib, adult patients with advanced\/metastatic solid tumors received escalating doses of modakafusp alfa 0.1\u20131.5 mg\/kg intravenously every 3 weeks (Q3W) across six dosing cohorts. In phase II, patients with unresectable\/metastatic cutaneous melanoma and resistance to \u22642 anti-PD-1 therapies in the metastatic setting received modakafusp alfa 1 mg\/kg Q3W in combination with pembrolizumab Q6W. Primary objectives were to determine the safety\/tolerability as a single agent in phase I, and efficacy in combination with pembrolizumab in phase II.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n A total of 21 and 24 patients were enrolled across phases Ib and II, respectively. The recommended phase II dose of modakafusp alfa was 1 mg\/kg. The most common drug-related adverse events were infusion-related reactions (IRRs; 52.4%) and thrombocytopenia (28.6%) in phase Ib; and headache (58.3%), fatigue (54.2%), IRRs (41.7%), neutropenia (37.5%), and nausea (33.3%) in phase II. In phase Ib, seven patients had a best response of stable disease (SD); in phase II, one patient had a confirmed complete response, one had a confirmed partial response, and seven had SD. All immunogenicity-evaluable patients were anti-drug antibodies (ADAs) positive following treatment with modakafusp alfa; neutralizing ADAs were reported in 82.4% and 90.9% of patients in phases Ib and II, respectively, which was associated with drug exposure reduction. Pharmacodynamic analyses demonstrated innate and adaptive immune activation in peripheral blood and within tumors. Paired biopsy analysis revealed two subgroups of patients defined by differences in CD38 upregulation, accompanied by differential intratumoral pharmacodynamic changes. Correlative analysis was inconclusive.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Modakafusp alfa induces innate and adaptive immune responses, supporting its hypothesized mechanism of action (MoA) in patients with advanced solid tumors. High immunogenicity and the potentially limited treatment effect of the interferon MoA may have contributed to limited efficacy in these patients.<\/jats:p>\n <\/jats:sec>\n \n Clinical trial registration<\/jats:title>\n \n https:\/\/clinicaltrials.gov\/study\/NCT04157517<\/jats:ext-link>\n , identifier NCT04157517.\n <\/jats:related-object>\n <\/jats:sec>","DOI":"10.3389\/fonc.2025.1620987","type":"journal-article","created":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T11:59:17Z","timestamp":1765195157000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["A phase Ib\/II study of modakafusp alfa alone and in combination with pembrolizumab in patients with advanced or metastatic solid tumors"],"prefix":"10.3389","volume":"15","author":[{"given":"David","family":"Gill","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles L.","family":"Cowey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory A.","family":"Daniels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Sommerhalder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raghad","family":"Abdul-Karim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Kirkwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Kolodney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inderjit","family":"Mehmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Roberts-Thomson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Strauss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sajeve","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Whitman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meredith","family":"McKean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gurpanna","family":"Saggu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shining","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Parot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jid.2020.03.943","article-title":"Treatment of advanced melanoma in 2020 and beyond","volume":"141","author":"Jenkins","year":"2021","journal-title":"J Invest Dermatol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01136","article-title":"Systemic therapy for melanoma: ASCO guideline update","volume":"41","author":"Seth","year":"2023","journal-title":"J Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.07.004","article-title":"ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee","volume":"31","author":"Keilholz","year":"2020","journal-title":"Ann Oncol"},{"key":"B4","volume-title":"Guidelines. Melanoma: assessment and management","year":"2022"},{"key":"B5","unstructured":"KEYTRUDA prescribing information"},{"key":"B6","unstructured":"KEYTRUDA summary of product characteristics"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary adaptive, and acquired resistance to cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell."},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-1033","article-title":"CD38-mediated immunosuppression as a mechanism of tumor cell escape from PD-1\/PD-L1 blockade","volume":"8","author":"Chen","year":"2018","journal-title":"Cancer Discov"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23251","article-title":"Practical guidelines for the management of interferon-\u03b1-2b side effects in patients receiving adjuvant treatment for melanoma","volume":"112","author":"Hauschild","year":"2008","journal-title":"Cancer"},{"key":"B10","first-page":"3","article-title":"Parkinson D A perspective on the clinical effectiveness and tolerance of interferon-alpha","volume":"25","author":"Borden","year":"1998","journal-title":"Semin Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024026124","article-title":"Targeted interferon therapy with modakafusp alfa for relapsed or refractory multiple myeloma","volume":"145","author":"Vogl","year":"2024","journal-title":"Blood."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2052658","DOI":"10.1080\/21645515.2022.2052658","article-title":"Anti CD38 monoclonal antibodies for multiple myeloma treatment","volume":"18","author":"Gozzetti","year":"2022","journal-title":"Hum Vaccin Immunother."},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000975280.98608.35","article-title":"PB2129: The modakafusp alfa iinnovate clinical development program: Rationale and design of 3 phase 1\/2 trials of an innate immunity enhancer for multiple myeloma (MM)","volume":"7","author":"Holstein","year":"2023","journal-title":"HemaSphere."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-141219","article-title":"TAK-573, an anti-CD38\/attenuated ifn\u03b1 fusion protein, has clinical activity and modulates the ifn\u03b1 receptor (IFNAR) pathway in patients with relapsed\/refractory multiple myeloma","volume":"136","author":"Vogl","year":"2020","journal-title":"Blood."},{"key":"B15","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3390\/cells9010026","article-title":"The roles of CD38 and CD157 in the solid tumor microenvironment and cancer immunotherapy","volume":"9","author":"Wo","year":"2019","journal-title":"Cells"},{"key":"B16","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1186\/s12967-024-05768-6","article-title":"CD38 as theranostic target in oncology","volume":"22","author":"Bocuzzi","year":"2024","journal-title":"J Transl Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0321622","article-title":"CD38-targeted attenuated interferon alpha immunocytokine activates both innate and adaptive immune cells to drive anti-tumor activity","volume":"20","author":"Sampson","year":"2025","journal-title":"PloS One"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.2503","article-title":"Dose escalation of a phase 1b\/2 study of modakafusp alfa, an immune-targeting attenuated cytokine, in patients (pts) with metastatic solid tumors","volume":"40","author":"Johnson","year":"2022","journal-title":"J Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1290060","article-title":"IFN-\u03b1 in the treatment of melanoma","volume":"189","author":"Tarhini","year":"2012","journal-title":"J Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0162472","article-title":"Targeting attenuated interferon-\u03b1 to myeloma cells with a CD38 antibody induces potent tumor regression with reduced off-target activity","volume":"11","author":"Pogue","year":"2016","journal-title":"PloS One"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddv071","article-title":"A robust type I interferon gene signature from blood RNA defines quantitative but not qualitative differences between three major IFN\u03b2 drugs in the treatment of multiple sclerosis","volume":"24","author":"Harari","year":"2015","journal-title":"Hum Mol Genet"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000843616.11738.cb","article-title":"S181: Modakafusp alfa (TAK-573): Updated clinical, pharmacokinetic (PK), and immunogenicity results from a phase 1\/2 study in patients (pts) with relapsed\/refractory multiple myeloma (RRMM)","volume":"6","author":"Kaufman","year":"2022","journal-title":"HemaSphere"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-3436","article-title":"Pembrolizumab plus pegylated interferon alfa-2b or ipilimumab for advanced melanoma or renal cell carcinoma: dose-finding results from the phase Ib KEYNOTE-029 study","volume":"24","author":"Atkins","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2014.11.008","article-title":"The use of interferon in melanoma patients: A systematic review","volume":"26","author":"Di Trolio","year":"2015","journal-title":"Cytokine Growth Factor Rev"},{"key":"B25","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1200\/JCO.1996.14.1.7","article-title":"Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684","volume":"14","author":"Kirkwood","year":"1996","journal-title":"J Clin Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13061353","article-title":"Immune system alterations in multiple myeloma: molecular mechanisms and therapeutic strategies to reverse immunosuppression","volume":"13","author":"D\u00edaz-Tejedor","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/cts.70296","article-title":"Population pharmacokinetic and pharmacokinetic-pharmacodynamic modeling of serum M-protein response for modakafusp alfa in a phase 1\/2 study of patients with relapsed or refractory multiple myeloma","volume":"18","author":"Li","year":"2025","journal-title":"Clin Trans Sci"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2112258118","article-title":"PD-L1 sustains chronic, cancer cell-intrinsic responses to type I interferon, enhancing resistance to DNA damage","volume":"118","author":"Cheon","year":"2021","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1436576","article-title":"Unraveling IFI44L\u2019s biofunction in human disease","volume":"14","author":"Du","year":"2024","journal-title":"Front Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.02582-24","article-title":"Interference without interferon: interferon-independent induction of interferon-stimulated genes and its role in cellular innate immunity","volume":"15","author":"Swaraj","year":"2024","journal-title":"mBio."},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathol-031920-093932","article-title":"Opposing roles of type I interferons in cancer immunity","volume":"16","author":"Boukhaled","year":"2021","journal-title":"Annu Rev Pathol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024027873","article-title":"A phase 2, randomized study of modakafusp alfa as a single agent in patients with relapsed\/refractory multiple myeloma","volume":"146","author":"Holstein","year":"2025","journal-title":"Blood."}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1620987\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T11:59:18Z","timestamp":1765195158000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1620987\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,8]]},"references-count":32,"alternative-id":["10.3389\/fonc.2025.1620987"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1620987","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,8]]},"article-number":"1620987"}}